Botulinum Toxin Type A: A Therapeutic Alternative for Trigeminal Neuralgia – A Literature-Based Overview
DOI:
https://doi.org/10.12775/QS.2024.26.55068Keywords
botulinum toxins, trigeminal neuralgia, neuralgia, facial painAbstract
Trigeminal neuralgia (TN) stands as one of the most prevalent forms of craniofacial pain. It commonly targets the areas supplied by the maxillary or mandibular divisions of the trigeminal nerve. Even the slightest stimulation, such as gentle touch can result in severe pain and incapacitation for the patient.
The etiology of TN encompasses idiopathic, classic, and secondary classifications. The most common form is the classical type.
Carbamazepine and oxcarbazepine are typically the initial pharmacological interventions prescribed for TN, offering relief for many individuals. Considering evidence of varying quality, medications such as lamotrigine, gabapentin, botulinum toxin type A, pregabalin, baclofen, and phenytoin could be viable options, either alone or in combination with carbamazepine or oxcarbazepine, if initial treatments prove ineffective or intolerable. Botulinum toxin type A therapy has shown high efficacy without severe adverse events in alleviating pain in patients with trigeminal neuralgia.
This article aims to provide a literature-based overview of trigeminal neuralgia, outlining its unique characteristics, etiology, epidemiology, classification, and management especially using botulinum neurotoxin A.
References
Möller M, May A. The unique role of the trigeminal autonomic reflex and its modulation in primary headache disorders. Curr Opin Neurol. 2019;32(3):438-442. doi:10.1097/WCO.0000000000000691
Shankland WE. The Trigeminal Nerve. Part I: An Over-View. Cranio - Journal of Craniomandibular and Sleep Practice. 2000;18(4):238-248. doi:10.1080/08869634.2000.11746137
Huff T, Weisbrod LJ, Daly DT. Neuroanatomy, Cranial Nerve 5 (Trigeminal). StatPearls. Published online November 9, 2022. Accessed April 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482283/
Peris-Celda M, Perry A, Carlstrom LP, Graffeo CS, Driscoll CLW, Link MJ. Key anatomical landmarks for middle fossa surgery: a surgical anatomy study. J Neurosurg. 2018;131(5):1561-1570. doi:10.3171/2018.5.JNS1841
Cruccu G, Di Stefano G, Truini A. Trigeminal Neuralgia. Ropper AH, ed. N Engl J Med. 2020;383(8):754-762. doi:10.1056/NEJMRA1914484
Jones MR, Urits I, Ehrhardt KP, et al. A Comprehensive Review of Trigeminal Neuralgia. Curr Pain Headache Rep. 2019;23(10). doi:10.1007/S11916-019-0810-0
Obermann M. Treatment options in trigeminal neuralgia. Ther Adv Neurol Disord. 2010;3(2):107. doi:10.1177/1756285609359317
Yoshimasu F, Kurland LT, Elveback LR. Tic douloureux in Rochester, Minnesota, 1945-1969. Neurology. 1972;22(9):952-956. doi:10.1212/WNL.22.9.952
Katusic S, Beard CM, Bergstralth E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990;27(1):89-95. doi:10.1002/ANA.410270114
Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal Neuralgia: Basic and Clinical Aspects. Curr Neuropharmacol. 2020;18(2):109-119. doi:10.2174/1570159X17666191010094350
Rubis A, Juodzbalys G. The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review. J Oral Maxillofac Res. 2020;11(2):2. doi:10.5037/JOMR.2020.11202
Di Stefano G, Maarbjerg S, Nurmikko T, Truini A, Cruccu G. Triggering trigeminal neuralgia. Cephalalgia. 2018;38(6):1049-1056. doi:10.1177/0333102417721677
Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014;54(10):1574-1582. doi:10.1111/HEAD.12441
Gambeta E, Chichorro JG, W. Zamponi G. Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments. Mol Pain. 2020;16. doi:10.1177/1744806920901890
Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19(9):784-796. doi:10.1016/S1474-4422(20)30233-7
Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26(6):831-849. doi:10.1111/ENE.13950
Zakrzewska JM, Wu J, Mon-Williams M, Phillips N, Pavitt SH. Evaluating the impact of trigeminal neuralgia. Pain. 2017;158(6):1166-1174. doi:10.1097/J.PAIN.0000000000000853
Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968;19(2):129-136. doi:10.1001/ARCHNEUR.1968.00480020015001
Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;2014(4). doi:10.1002/14651858.CD005451.PUB3
Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966;29(3):265-267. doi:10.1136/JNNP.29.3.265
Bick SKB, Eskandar EN. Surgical Treatment of Trigeminal Neuralgia. Neurosurg Clin N Am. 2017;28(3):429-438. doi:10.1016/j.nec.2017.02.009
Sade B, Lee JH. Microvascular decompression for trigeminal neuralgia. Neurosurg Clin N Am. 2014;25(4):743-749. doi:10.1016/J.NEC.2014.06.007
Missios S, Mohammadi AM, Barnett GH. Percutaneous treatments for trigeminal neuralgia. Neurosurg Clin N Am. 2014;25(4):751-762. doi:10.1016/J.NEC.2014.06.008
Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-1028. doi:10.1111/J.1468-1331.2008.02185.X
Bohman LE, Pierce J, Stephen JH, Sandhu S, Lee JYK. Fully endoscopic microvascular decompression for trigeminal neuralgia: technique review and early outcomes. Neurosurg Focus. 2014;37(4). doi:10.3171/2014.7.FOCUS14318
Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015;20(2):107-114. doi:10.17712/NSJ.2015.2.20140501
Morra ME, Elgebaly A, Elmaraezy A, et al. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17(1). doi:10.1186/S10194-016-0651-8
Li S, Lian YJ, Chen Y, et al. Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain. 2014;15(1):1-6. doi:10.1186/1129-2377-15-43
Fujinaga Y, Inoue K, Oguma K. Structure and function of Clostridium botulinum toxins. Microbiol Immunol. 1995;39(3):161-168. doi:10.1111/J.1348-0421.1995.TB02184.X
Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 2000;82(5):427-446. doi:10.1016/S0300-9084(00)00216-9
Lakhan SE, Velasco DN, Tepper D. Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis. Pain Med. 2015;16(9):1773-1780. doi:10.1111/PME.12728
Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting--a review of the literature. Pain Pract. 2008;8(4):269-276. doi:10.1111/J.1533-2500.2008.00202.X
Aoki KR. Future aspects of botulinum neurotoxins. J Neural Transm (Vienna). 2008;115(4):567-573. doi:10.1007/S00702-007-0758-9
Xia JH, He CH, Zhang HF, et al. Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci. 2016;126(4):348-353. doi:10.3109/00207454.2015.1019624
Tereshko Y, Valente M, Belgrado E, et al. The Therapeutic Effect of Botulinum Toxin Type A on Trigeminal Neuralgia: Are There Any Differences between Type 1 versus Type 2 Trigeminal Neuralgia? Toxins (Basel). 2023;15(11). doi:10.3390/toxins15110654
Bohluli B, Motamedi MHK, Bagheri SC, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(1):47-50. doi:10.1016/J.TRIPLEO.2010.04.043
Zhang H, Lian Y, Xie N, Chen C, Zheng Y. Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study. J Headache Pain. 2017;18(1). doi:10.1186/S10194-017-0793-3
Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15(1). doi:10.1186/1129-2377-15-65
Türk Ü, Ilhan S, Alp R, Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 2005;28(4):161-162. doi:10.1097/01.WNF.0000172497.24770.B0
Zúñiga C, Piedimonte F, Díaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36(5):146-150. doi:10.1097/WNF.0B013E31829CB60E
Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141(1-2):60-69. doi:10.1016/J.PAIN.2008.10.005
Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14(1):92. doi:10.1186/1129-2377-14-92
Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443-450. doi:10.1177/0333102412441721
Piovesan EJ, Teive HG, Kowacs PA, Della Coletta M V., Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65(8):1306-1308. doi:10.1212/01.WNL.0000180940.98815.74
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Natalia Wierzejska, Mikołaj Domański, Barbara Kopczyńska, Oliwia Czyżniewska, Karolina Czupryńska, Karina Otręba, Julia Szałajska, Maria Wojcieszek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 80
Number of citations: 0
